Blocking the Chemokine CCL5 Reduces Inflammation and Pain in a Mouse Model of Nerve Injury | Research

The takeaway

The chemokine receptor antagonist Met-RANTES reduced pain hypersensitivity, macrophage infiltration, and pro-inflammatory cytokine levels while increasing anti-inflammatory IL-10 in a mouse model of neuropathic pain.

IL-10 significantly increased
Met-RANTES treatment shifted the immune balance at nerve injury sites from pro-inflammatory to anti-inflammatory, with increased IL-10 and decreased TNFα, IL-1β, IL-6, and IFNγ.

What the researchers found

Met-RANTES-treated mice showed significantly less behavioral hypersensitivity (pain) after partial sciatic nerve ligation. At the molecular level, treatment significantly reduced macrophage infiltration at the injury site, decreased secretion of pro-inflammatory cytokines (TNFα, IL-1β, IL-6, and IFNγ), and increased anti-inflammatory IL-10 levels.

Expression of opioid peptides — enkephalin, β-endorphin, and dynorphin mRNA — in damaged nerves was also significantly decreased in treated mice, suggesting that reducing inflammation reduced the compensatory opioid peptide response. The results demonstrate that CCL5 regulates the inflammatory microenvironment controlling pain sensitivity at the peripheral nerve injury site.

Why it matters

Neuropathic pain is notoriously difficult to treat, and current therapies are often inadequate or carry addiction risks. This study identifies CCL5 as a key driver of the inflammatory environment that causes pain at nerve injury sites and demonstrates that blocking it with a peptide-based antagonist can reduce both inflammation and pain. This points to a potential new therapeutic strategy for chronic pain.

How the study worked

Mice underwent partial sciatic nerve ligation to create a neuropathic pain model. Met-RANTES (a selective CCL5 receptor antagonist) was administered via intraperitoneal injection. Researchers measured behavioral pain responses, quantified immune cell infiltration using flow cytometry and immunohistochemistry, measured cytokine protein levels (TNFα, IL-1β, IL-6, IFNγ, IL-10), and assessed opioid peptide mRNA expression (enkephalin, β-endorphin, dynorphin) using real-time PCR in damaged nerves.

What this study cannot tell us

The study was conducted in mice, and results may not directly translate to human neuropathic pain. Only peritoneal (systemic) administration was tested, so local delivery effects are unknown. The study used a single neuropathic pain model (partial sciatic nerve ligation), and results may differ in other pain conditions. Long-term effects and potential for immunosuppression with chronic CCL5 blockade were not assessed. Sample sizes were not specified in the abstract.

How to read the evidence

This is a preclinical animal study using a well-established mouse neuropathic pain model. The mechanistic data are comprehensive, but the findings have not been validated in human patients or clinical trials.

When this study was published

Published in 2013, this study was early in establishing the CCL5/RANTES pathway as a pain target. Subsequent research has continued to explore chemokine receptor antagonism for chronic pain.

The bigger picture

Chemokine signaling is increasingly recognized as a therapeutic target for chronic pain. This study highlights the CCL5/RANTES pathway as a key regulator of peripheral nerve inflammation and pain. Peptide-based chemokine receptor antagonists like Met-RANTES offer a targeted approach to modulating immune responses at injury sites without broadly suppressing the immune system, which could offer advantages over current anti-inflammatory pain treatments.

Questions still open

Would local delivery of Met-RANTES directly to the nerve injury site be more effective than systemic administration?
Could CCL5 receptor antagonists be effective for neuropathic pain conditions in humans?
Does chronic CCL5 blockade carry risks of immunosuppression at injury sites that need immune surveillance?

Common questions

What is Met-RANTES and how does it work?

Met-RANTES is a modified version of the natural chemokine CCL5 (RANTES) that blocks the receptors CCL5 normally activates. By blocking these receptors, Met-RANTES prevents CCL5 from attracting inflammatory immune cells to nerve injury sites, reducing the inflammation that contributes to chronic pain.

Could blocking chemokines be a new way to treat chronic pain?

This study suggests yes. By targeting the specific chemokine (CCL5) that drives inflammation at nerve injury sites, researchers reduced pain without using opioids. This approach is more targeted than general anti-inflammatory drugs and could offer a new strategy for managing neuropathic pain, though human clinical trials are needed.

Read the original research

Peritoneal administration of Met-RANTES attenuates inflammatory and nociceptive responses in a murine neuropathic pain model.

The journal of pain, 14(1), 24-35

View on PubMed ↗Publisher’s paper ↗

Citation

Liou, Jiin-Tarng; Mao, Chih-Chieh; Ching-Wah Sum, Daniel; Liu, Fu-Chao; Lai, Ying-Shu; Li, Jui-Chin; Day, Yuan-Ji. (2013). Peritoneal administration of Met-RANTES attenuates inflammatory and nociceptive responses in a murine neuropathic pain model.. The journal of pain, 14(1), 24-35. https://doi.org/10.1016/j.jpain.2012.09.015